Zobrazeno 1 - 10
of 202
pro vyhledávání: '"Le Guennec S"'
Publikováno v:
Journal of Physics: Conference Series; 2024, Vol. 2767 Issue 1, p1-10, 10p
Background: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::d9c2f582489791b10d9d97a07b2ad870
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121675
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121675
Autor:
Schjesvold F; Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA., Facon T; Lille University Hospital, Lille, France., Alegre A; Hospital Universitario La Princesa and Hospital Quironsalud, Madrid, Spain., Spencer A; Department of Clinical Hematology, Alfred Health-Monash University, Melbourne, Australia., Jurczyszyn A; Department of Hematology, Jagiellonian University Medical College, Krakow, Poland., Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan., Frenzel L; Hôpital Necker-Enfants Malades, Paris, France., Min CK; Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of South Korea., Guillonneau S; Sanofi CMO, Chilly-Mazarin, France., Lin PL; Sanofi Global Oncology, Cambridge, MA, USA., Le-Guennec S; Sanofi RD, Vitry-sur-Seine, France., Campana F; Sanofi RD, Cambridge, MA, USA., Van de Velde H; Sanofi RD, Cambridge, MA, USA., Bensfia S; Sanofi Global Oncology, Cambridge, MA, USA., Bringhen S; Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. sarabringhen@yahoo.com.
Publikováno v:
Haematologica [Haematologica] 2022 Mar 01; Vol. 107 (3), pp. 774-775. Date of Electronic Publication: 2022 Mar 01.
Autor:
Richardson PG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Harrison SJ; Peter MacCallum Cancer Centre & Royal Melbourne Hospital Melbourne, Sir Peter MacCallum Department of Oncology, University of Melbourne Parkville, Victoria, 3010, Australia., Bringhen S; Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino 10126, Italy., Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo 0188, Norway.; KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo 0315, Norway., Yong K; Department of Haematology, University College London Hospitals, London WC1N 3BG, UK., Campana F; Sanofi R&D, Cambridge, MA 02142, USA.; Currently, Takeda Pharmaceuticals, Cambridge, MA 02142, USA., Le-Guennec S; Sanofi R&D, Vitry-sur-Seine 94400, France., Macé S; Sanofi R&D, Vitry-sur-Seine 94400, France., Dimopoulos MA; Department of Clinical Therapeutics, National & Kapodistrian University of Athens, Athens 157 72, Greece.
Publikováno v:
Future oncology (London, England) [Future Oncol] 2021 Dec; Vol. 17 (34), pp. 4797-4812. Date of Electronic Publication: 2021 Sep 15.
Autor:
Hulin C; Department of Hematology, Hospital De Haut Leveque, University Hospital, Pessac, France. cyrille.hulin@chu-bordeaux.fr.; Ankara University School of Medicine, Department of Hematology, Ankara, Turkey. cyrille.hulin@chu-bordeaux.fr., Beksac M; Waikato Hospital, Hamilton, New Zealand., Goodman HJ; First Faculty of Medicine, Charles University and General Hospital, First Department of Medicine, Department of Hematology, Prague, Czech Republic., Spicka I; Hematology Service, University Hospital La Princesa, Madrid, Spain., Alegre A; University of Melbourne, Epworth Healthcare, Melbourne, Australia., Prince M; Sanofi, Cambridge, Mass, USA., Campana F; Sanofi Oncology, Cambridge, MA, USA.; Sanofi, Montpellier, France., Finn G; Sanofi Oncology, Cambridge, MA, USA., Le-Guennec S; Sanofi R&D, Vitry-sur-seine, France., Macé S; Sanofi R&D, Vitry-sur-seine, France., Muccio S; Sanofi R&D, Vitry-sur-seine, France., Tavernier A; Sanofi R&D, Vitry-sur-seine, France., Rouchon MC; Sanofi R&D, Vitry-sur-seine, France.; Sanofi, Montpellier, France., Richardson PG; Sanofi, Montpellier, France.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2021 Oct 20; Vol. 11 (10), pp. 169. Date of Electronic Publication: 2021 Oct 20.
Autor:
Bringhen S; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. Electronic address: sarabringhen@yahoo.com., Pour L; Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Vorobyev V; S.P. Botkin Hospital, Moscow, Russia., Vural F; Ege University Medical Faculty, Izmir, Turkey., Warzocha K; Instytut Hematologii i Transfuzjologii, Warsaw, Poland., Benboubker L; Department of Hematology, University Hospital Tours, Tours, France., Koh Y; Seoul National University Hospital, Seoul, South Korea., Maisnar V; Charles University Hospital, Hradec Kralove, Czech Republic., Karlin L; Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, France., Pavic M; University of Sherbrooke, Sherbrooke, QC, Canada., Campana F; Sanofi, Cambridge, MA, USA., Le Guennec S; Sanofi R&D, Vitry-sur-Seine, France., Menas F; Aixial (for Sanofi), Boulogne-Billancourt, France., van de Velde H; Sanofi, Cambridge, MA, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Publikováno v:
Leukemia research [Leuk Res] 2021 May; Vol. 104, pp. 106576. Date of Electronic Publication: 2021 Mar 29.
Autor:
Schjesvold FH; Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Norway., Richardson PG; Dana-Farber Cancer Institute, Boston, MA., Facon T; Lille University Hospital, Lille, France., Alegre A; Hospital Universitario La Princesa and Hospital Quironsalud, Madrid., Spencer A; Alfred Health-Monash University, Melbourne, Australia., Jurczyszyn A; Jagiellonian University Medical College, Krakow, Poland., Sunami K; National Hospital Organization Okayama Medical Center, Okayama, Japan., Frenzel L; Hôpital Necker-Enfants Malades, Paris, France., Min CK; Seoul St. Mary Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South)., Guillonneau S; Sanofi CMO, Chilly-Mazarin, France., Lin PL; Sanofi Global Oncology, Cambridge, MA., Le-Guennec S; Sanofi R-D, Vitry-sur-Seine, France., Campana F; Sanofi R-D, Cambridge, MA., van de Velde H; Sanofi RD, Cambridge, MA., Bensfia S; Sanofi Global Oncology, Cambridge, MA., Bringhen S; University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino.
Publikováno v:
Haematologica [Haematologica] 2021 Apr 01; Vol. 106 (4), pp. 1182-1187. Date of Electronic Publication: 2021 Apr 01.
Autor:
Gharib, Ehsan1,2 (AUTHOR) ehsangharib55@gmail.com, Robichaud, Gilles A.1,2 (AUTHOR) ehsangharib55@gmail.com
Publikováno v:
International Journal of Molecular Sciences. Sep2024, Vol. 25 Issue 17, p9463. 124p.
Autor:
Attal M; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France. Electronic address: attal.michel@iuct-oncopole.fr., Richardson PG; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: paul_richardson@dfci.harvard.edu., Rajkumar SV; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA., San-Miguel J; Clinical and Translational Medicine, Clínica Universidad de Navarra, Navarra, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain., Beksac M; Department of Hematology, Ankara University, Ankara, Turkey., Spicka I; 1st Department of Medicine, Department of Hematology, First Faculty of Medicine Charles University and General Hospital in Prague, Prague, Czech Republic., Leleu X; Department of Haematology, CHU La Milétrie-Poitiers, Poitiers, France., Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway., Moreau P; Hematology Department, CHU Nantes, Nantes, France., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Huang JS; Department of Hematology, National Taiwan University Hospital, Taiwan., Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic., Cavo M; Department of Experimental, Diagnostic and Specialty Medicine, Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy., Prince HM; Cancer Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia., Macé S; Sanofi Research And Development, Vitry-Sur-Seine, France., Corzo KP; Sanofi-Genzyme Oncology, Cambridge, MA, USA., Campana F; Sanofi-Genzyme Oncology, Cambridge, MA, USA., Le-Guennec S; Sanofi Research And Development, Vitry-Sur-Seine, France., Dubin F; Sanofi Research And Development, Vitry-Sur-Seine, France., Anderson KC; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Publikováno v:
Lancet (London, England) [Lancet] 2019 Dec 07; Vol. 394 (10214), pp. 2096-2107. Date of Electronic Publication: 2019 Nov 14.
Autor:
Richardson PG; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5450, USA., Attal M; Department of Hematology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France., Campana F; Sanofi, Cambridge, MA 02142, USA., Le-Guennec S; Sanofi, Vitry-Alfortville, France., Hui AM; Sanofi, Cambridge, MA 02142, USA., Risse ML; Sanofi, Vitry-Alfortville, France., Corzo K; Sanofi, Cambridge, MA 02142, USA., Anderson KC; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5450, USA.
Publikováno v:
Future oncology (London, England) [Future Oncol] 2018 May; Vol. 14 (11), pp. 1035-1047. Date of Electronic Publication: 2017 Dec 22.